Agilus Diagnostics Appoints Vijender Singh as Managing Director & CEO Amid Leadership Change

Agilus Diagnostics Appoints Vijender Singh as Managing Director & CEO Amid Leadership Change​

Gurugram, July 20, 2026 – Agilus Diagnostics, a prominent diagnostic service provider in India, has announced the appointment of Mr. Vijender Singh as its new Managing Director and Chief Executive Officer (CEO). This appointment follows the departure of Dr. Anand K, who had served with the organization for nearly six years. The Board and management extended gratitude to Dr. Anand K for his contributions while wishing him success in his future endeavors.

Mr. Vijender Singh brings over three decades of leadership experience across various sectors, including diagnostics, healthcare, consumer healthcare, and FMCG. He is noted for his proven ability to scale businesses, enhance operational excellence, strengthen governance frameworks, and build high performing organizations.

Prior to this role, Mr. Singh held key positions such as Chairman and Managing Director at Diagnum Healthcare, focusing on strategic growth and business development. His executive background also includes serving as Group CEO of Metropolis Healthcare and CEO of Healthians. He previously spent nearly a decade with Dr. Lal PathLabs, where he was instrumental in building one of India's successful diagnostics platforms.

Dr. Ashutosh Raghuvanshi, Managing Director and Chief Executive Officer of Fortis Healthcare Limited and Chairman of Agilus Diagnostics, commented on the appointment, stating that they are delighted to welcome Mr. Singh. He noted that Vijender’s extensive experience in building and scaling diagnostic businesses, coupled with his deep understanding of the industry, makes him ideally positioned to lead Agilus through its next phase of growth. Dr. Raghuvanshi added that he believes his leadership will strengthen capabilities and accelerate innovation within the diagnostics landscape.

Commenting on joining Agilus Diagnostics, Mr. Vijender Singh expressed excitement about taking the helm during a time of significant transformation and growth in the diagnostics industry. He stated that he looks forward to working with the team to reinforce the organization’s market position, expand access to high quality diagnostics, and create long term value for patients, customers, and stakeholders.

Operational Profile of Agilus Diagnostics​

Agilus Diagnostics, a subsidiary of Fortis Healthcare Ltd., is one of India's leading diagnostic service providers. The company, instituted in 1995, has undergone a brand transformation journey and offers over 3,000 tests and test combinations, ranging from routine to genetic tests.

As of March 31, 2023, Agilus Diagnostics maintained extensive operational reach across India:


Furthermore, the company holds a significant number of NABL accreditations as of March 31, 2023: 43 NABL accredited labs, 3 NABL M(EL)T certified labs, and 2 CAP accredited labs. Agilus Diagnostics also has an international network spanning centers across the SAARC region, Sub-Saharan Africa, South East Asia, and the Middle East.

Fortis Healthcare Overview​

Fortis Healthcare Limited is a leading integrated healthcare delivery service provider in India, with healthcare verticals covering hospitals, diagnostics, and day care specialty facilities. The company currently operates 36 healthcare facilities across 12 states and union territories. Its network includes over 6,000 operational beds and 400 diagnostics labs.

FORTIS Stock Price Movement​

Fortis Healthcare Limited shares edged higher in post-market trading, settling at ₹951.20 after gaining 0.58% today. The stock traded within a range of ₹948.8 to ₹960.10 amid a volume of 532,831 shares.